In an open-label , multicentre study , patients receiving 2NRTI plus PI for at least 6 months , with a history of undetectable plasma HIV-1 RNA since the initiation of therapy and plasma HIV-1 RNA < 50 copies/ml at screening , were randomly assigned to replace the PI with abacavir ( n = 105 ) or continue the same treatment ( n = 106 ) .
